With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 ...
Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...
Shares of Moderna rose after the company said that the government of Canada authorized its updated Covid-19 vaccine, joining the U.S. in the approval. The stock was up 4.5% at $72.28 in Tuesday ...
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...